Mayo Clinic first in U.S. to offer lymphoma genomic diagnostic test for patients

PHOENIX ? Mayo Clinic has created a genetic test to help guide diagnosis and treatment of patients with diffuse large B-cell lymphoma, the most common type of non-Hodgkin?s lymphoma. The Lymph2Cx test helps determine where the lymphoma started, assigning ?cell-of-origin? groups using a 20-gene expression-based assay. It is the first test to go into the [...]
Source: Mayo Clinic Business News - Category: Pharmaceuticals Source Type: news